Key Segmentation
By Product Type
-
Diagnostic and Monitoring Devices
-
Therapeutic Devices
By Application
-
Home Healthcare
-
Remote Patient Monitoring
-
Sports and Fitness
By Grade Type
-
Consumer-Grade
-
Clinical-Grade
By Distribution Channel
-
Pharmacies
-
Online
-
Hypermarkets and Supermarkets
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Abbott Laboratories, Dexcom, Medtronic, Insulet, Tandem Diabetes Care, Beta Bionics, Senseonics, iRhythm Technologies, Apple, Samsung Electronics, Google (Fitbit), Withings, Koninklijke Philips, Biotricity, BioIntelliSense and Garmin.
Key opportunities include over-the-counter glucose and blood pressure sensing, artificial intelligence analytics, pharmacy and online sales, and growth in emerging markets.
Rising chronic disease prevalence, together with reimbursed remote patient monitoring and continuous sensor technology, is the main growth factor.
By Product Type, the Diagnostic and Monitoring Devices segment dominated the market in 2025 with an estimated 61.15% share, supported by wide use of glucose, cardiac and blood pressure monitoring.
North America dominated the market with a share of 40.35% in 2025, driven by high chronic disease prevalence, insurance coverage and early adoption of digital health.